Inactive Instrument

Sonoma Pharmaceuticals Inc Stock Nasdaq

Equities

US83558L1052

Pharmaceuticals

Sales 2024 * 14.65M Sales 2025 * 17.91M Capitalization 2.62M
Net income 2024 * -5M Net income 2025 * -3M EV / Sales 2024 * 0.18 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.15 x
P/E ratio 2024 *
-0.19 x
P/E ratio 2025 *
-0.37 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.44%
More Fundamentals * Assessed data
Dynamic Chart
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference CI
Sector Update: Health Care Stocks Ease in Late Afternoon MT
Sector Update: Health Care MT
Top MIdday Decliners MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board CI
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller CI
Earnings Flash (SNOA) SONOMA PHARMACEUTICALS Reports Q4 Revenue $3M MT
More news
Managers TitleAgeSince
Chief Executive Officer 57 19-09-26
Director of Finance/CFO 53 01-12-31
Director of Finance/CFO 56 20-09-07
Members of the board TitleAgeSince
Chief Executive Officer 57 19-09-26
Director/Board Member 79 07-04-19
Director/Board Member 64 18-09-18
More insiders
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
More about the company